首页 | 本学科首页   官方微博 | 高级检索  
检索        

曲美他嗪治疗冠心病合并糖尿病的疗效分析
引用本文:黄瑞芳,许韩波,黄狄娜.曲美他嗪治疗冠心病合并糖尿病的疗效分析[J].糖尿病新世界,2021(6):69-71.
作者姓名:黄瑞芳  许韩波  黄狄娜
作者单位:广东省揭阳市普宁市人民医院门诊药房;广东省揭阳市普宁市人民医院药学部
摘    要:目的探讨曲美他嗪治疗冠心病合并糖尿病患者的疗效。方法选择2018年2月—2020年1月期间该院收治的86例冠心病合并糖尿病患者作为研究对象,每组43例,对照组行常规治疗,观察组增加曲美他嗪治疗,记录心绞痛、左心室射血分数变化,测定血糖、糖化血红蛋白及胰岛素指数。结果治疗后,观察组心绞痛发作次数、持续时间降低且显著低于对照组,6MWD升高且显著高于对照组,差异有统计学意义(P<0.05);治疗后,观察组LVEF明显升高且显著高于对照组,LVEDD、LVESD、BNP明显降低且显著低于对照组,差异有统计学意义(P<0.05);治疗后,观察组血糖、HbA1c及HOMA-IR均显著降低且低于对照组,差异有统计学意义(P<0.05)。结论针对冠心病合并糖尿病患者采用曲美他嗪治疗可有效控制心绞痛发生,提高左心室射血分数,增强心功能,且控制血糖水平,改善胰岛素指数,控制病情进展。

关 键 词:曲美他嗪  冠心病  糖尿病  血糖  糖化血红蛋白  胰岛素指数

Analysis of the Curative Effect of Trimetazidine in the Treatment of Coronary Heart Disease Complicated with Diabetes
HUANG Ruifang,XU Hanbo,HUANG Dina.Analysis of the Curative Effect of Trimetazidine in the Treatment of Coronary Heart Disease Complicated with Diabetes[J].Diabetes New World,2021(6):69-71.
Authors:HUANG Ruifang  XU Hanbo  HUANG Dina
Institution:(Outpatient Pharmacy,Puning People's Hospital,Jieyang City,Puning,Guangdong Province,515300 China;Department of Pharmacy,Puning City People's Hospital,Jieyang City,Puning,Guangdong Province,515300 China)
Abstract:Objective To investigate the efficacy of trimetazidine in the treatment of coronary heart disease with diabetes.Methods The 86 patients with coronary heart disease and diabetes mellitus admitted to the hospital from February 2018 to January 2020 were selected as the research objects,43 cases in each group,the control group received conventional treatment,the observation group received trimetazidine treatment,and the angina pectoris and left ventricle were recorded Changes in ejection fraction,measurement of blood glucose,glycosylated hemoglobin and insulin index.Results After treatment,the number and duration of angina pectoris in the observation group decreased and were significantly lower than those in the control group,6MWD increased and was significantly higher than the control group,the difference was statistically significant(P<0.05);after treatment,the LVEF in the observation group increased significantly And significantly higher than the control group,LVEDD,LVESD,BNP were significantly reduced and significantly lower than the control group,the difference was statistically significant(P<0.05);after treatment,the observation group blood glucose,HbA1c and HOMA-IR were significantly lower and lower than In the control group,the difference was statistically significant(P<0.05).Conclusion Trimetazidine treatment for patients with coronary heart disease and diabetes can effectively control the occurrence of angina,increase left ventricular ejection fraction,enhance heart function,control blood glucose level,improve insulin index,and control disease progression.
Keywords:Trimetazidine  Coronary heart disease  Diabetes  Blood sugar  Glycosylated hemoglobin  Insulin index
本文献已被 CNKI 维普 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号